SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Summer Interns

IP-Watch interns talk about their Geneva experience in summer 2013. 2:42.

Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Latest Comments
  • So simply put, we have the NABP saying that all ph... »
  • The original Brustle decision was widely criticise... »

  • For IPW Subscribers

    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >


    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    World Health Assembly: WHO Carves Out Leadership Role In “Vaccine Decade”

    Published on 28 May 2012 @ 8:43 pm

    By for Intellectual Property Watch

    With a generous pledge and a grand vision, Bill Gates launched the “Decade of Vaccines” two years ago. By endorsing a “Global Vaccine Action Plan” during the World Health Assembly last week, the world’s health authority stands as the lead agency in advancing the initiative.

    The 65th World Health Assembly (WHA), which met 21-26 May, endorsed the Global Vaccine Action Plan (GVAP), a broad set of objectives, goals and guiding principles to increase worldwide access to immunisation.

    Although member states and stakeholders widely supported the plan, some said that greater attention needed to be given to addressing the high-cost of new vaccines and that products needed to be better adapted for use in developing countries. Others called for the need to hammer out details related to governance and financial implications.

    Vaccine Decade Origins

    The Bill and Melinda Gates Foundation launched the Decade of Vaccines (DoV) initiative in 2010 with a $10 billion pledge “to help research, develop and deliver vaccines for the world’s poorest countries” over the next ten years. The announcement received widespread support from the global health community and the Decade of Vaccines Collaboration was created to provide oversight in advancing the Gates’ vision.

    Members of the Decade of Vaccines Collaboration Leadership Council include: WHO Director General Margaret Chan, Global Alliance for Vaccines and Immunization (GAVI) CEO Seth Barkley, and President of the Global Development Program at the Bill and Melinda Gates Foundation, Christopher Elias.

    Last year during the 64th WHA, after Bill Gates addressed the Assembly (IPW, WHO, 17 May 2011), member states called for the development of a global vaccine action plan. With input from more than 1,100 people from 142 countries and 297 organisations, the DoV Collaboration drove the development of the draft Global Vaccine Action Plan. WHA agenda item A65/22 is available here.

    The Global Vaccine Action Plan says that “now is the time for showing commitment to achieving the full potential of immunization.” It points to the vision for the Decade of Vaccines, which is “to extend, by 2020 and beyond, the full benefit of immunization to all people, regardless of where they are born, who they are or where they live.”

    The action plan outlines goals, objectives, and guiding principles, and includes an estimate of resources required to realise the ambitious vision. The goals are: to achieve a world free of polio, meet global and regional elimination targets; meet vaccination coverage targets in every region, country and community; develop and introduce new and improved vaccines and technologies; and exceed the Millennium Development Goal 4 target for reducing child mortality. Guiding principles focus on country ownership, shared responsibility and partnership, equity, integration, sustainability, and innovation.

    Facing Immunisation Challenges

    During the 65th WHA committee meeting which reviewed the plan, several developing countries remarked that in order to introduce new vaccines, prohibitive pricing needed to be dealt with. In the statement from Thailand, this sentiment was underlined.

    “Another major structural barrier to ‘vaccine self-reliance’ in low- and middle-income countries is the high cost of new vaccines that are often monopolized. Adoption of new vaccines is not possible in resource constraint setting until a generic version of vaccines becomes available in the market, often 10 to 15 years after the first launch of new vaccines,” said the official from Thailand.

    To address the issue of affordability, the delegation from Thailand suggested that a strategy “to promote affordability” was needed, in particular “a range of incentive mechanisms to de-link the R&D cost and the vaccine price.”

    Thailand suggested that these issues could be reflected in the fifth strategic objective, which calls for immunisation programmes to have “sustainable access to predictable funding, quality supply and innovative technologies.” In this section, the action plan calls for innovative pricing and procurement mechanisms. But it does not specify the exploration of alternative options to the patent system, where the high cost of R&D is paid for through a time-limited monopoly on the exclusive rights of a vaccine, as Thailand’s delegation suggests.

    Other developing countries, including the African region, identified a need to address challenges in the overall healthcare landscape in order to achieve broad immunisation scale-up. Representing the African countries, the Egyptian delegation pointed to a lack of skilled workers and poor quality healthcare services.

    Médecins Sans Frontières (MSF, Doctors Without Borders) echoed the sentiment and provided examples of challenges in “reaching infants with even the basic package of vaccines.” Some 20 per cent of children go unvaccinated every year. MSF called on countries to address “the shortcomings of their immunisation programmes immediately.”

    Furthermore, MSF pointed to the need to develop products that are easier to use in developing countries. They cited a need for “adapted products that are more thermostable, easier to administer – that is without injection – and requiring fewer doses.” MSF’s statement to the committee is available here.

    One of the key principles of the Global Vaccine Action Plan is to place the responsibility of providing immunisations services for all in the hands of individual countries. The importance of country ownership, one of the six guiding principles of the plan, was emphasised by several public health stakeholders during a side event hosted by the International Federation of Pharmaceutical Manufactures and Associations (IFPMA) on 21 May.

    During the panel discussion, Ciro De Quadros, steering committee co-chair of the DoV Collaboration and executive vice president of the Sabin Vaccine Institute, said, “This has to be a country-owned program. We cannot continue anymore with activities that just come from the top down. And I think that countries are committed to that.”

    The Global Vaccine Action Plan also calls for the development of an accountability framework to ensure national ownership and measure progress. It specifies that starting in 2013, progress should be reviewed annually by country, the WHO regional committees, and the WHA.

    Calls for Further Discussions

    But some member states and stakeholders say the plan does not go far enough in defining responsibilities and detailing action items.

    During the 65th WHA, on behalf of the IFPMA, Laetitia Bigger, manager of vaccines policy, said that while the industry association supports the initiative, “further efforts should be undertaken to refine the plan.”

    This requires clarifying interaction vis-à-vis other global vaccine programs and partnerships; prioritizing objectives and identifying opportunities for synergies amongst them; and defining human and financial resource needs and funding sources. In addition, further dialogue is needed to develop an accountability framework, which would define stakeholders’ roles and responsibilities, targeted indicators and a monitoring process,” Bigger said. IFPMA’s statement is available here [pdf].

    Similarly, the EU delegation, while expressing support for the action, said, “We would like to understand better the proposed governance structure which is foreseen in the action plan and how it relates to other initiatives such as GAVI.” The EU official also said there was a need for discussions on the “financial implications of it.”

    According to a press release issued by the Decade of Vaccines Collaboration, further implementation details will emerge as the plan is adopted at the regional and country level, noting, “Country involvement in this process reinforces a key tenet of the GVAP, which is to increase ownership of immunization programs. The collaboration will also establish a monitoring and evaluation framework and finalize estimates for funding needs as well as potential cost savings.”

    Rachel Marusak Hermann may be reached at info@ip-watch.org.

     


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 54.82.53.231